George Golumbeski - Jun 10, 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
Brandon Marsh, as Attorney-in-Fact for George Golumbeski
Stock symbol
SAGE
Transactions as of
Jun 10, 2024
Transactions value $
$0
Form type
4
Date filed
6/11/2024, 04:58 PM
Previous filing
Jan 4, 2024
Next filing
Jun 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +12.5K $0.00 12.5K Jun 10, 2024 Common Stock 12.5K $10.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.